Price Prediction

Eli Lilly (LLY) Stock Price Prediction: Lilly’s earnings beat and higher guidance keep the bid intact, but momentum is pausing near resistance

Eli Lilly (LLY) traded at $1,429.31, down 1.94% on the day, even after a third-quarter beat and a full-year guidance lift on October 29, 2026. Barclays also raised its price target to $1,550, while...

Eli Lilly (LLY) Stock Price Prediction: Lilly’s earnings beat and higher guidance keep the bid intact, but momentum is pausing near resistance

Earnings and guidance still do the heavy lifting

Eli Lilly’s latest fundamental update remains the main anchor for the stock. On October 29, 2026, the company reported third-quarter revenue of $24.4 billion, up 39% year over year, and raised full-year 2026 revenue guidance to $91.0 billion to $92.0 billion. Management also lifted underlying non-GAAP EPS guidance at the midpoint by $4.07, citing strength in Mounjaro and Zepbound and noting roughly $900 million of Q3 benefits, including $410 million from Jardiance milestones.

That matters because the shares are still being priced as a growth stock, not a defensive compounder. A stronger top line and a higher guide give bulls a reason to keep paying up, but the bar is already high.

Analyst targets remain supportive, but not uniform

Barclays raised its price target on LLY to $1,550 from $1,400 and kept an overweight rating, implying roughly 6.28% upside from the prior close cited by MarketBeat. MarketBeat also described the broader analyst backdrop as “Moderate Buy” with an average price target of $1,422. CapEdge shows a higher average target of $1,477.85, with a wide range that stretches from $940 to $1,700. Jefferies maintained a Buy rating and lifted its target to $1,700 on November 9, 2026.

The message is straightforward: Street coverage is constructive, but targets are dispersed enough to show that expectations for Lilly’s next leg are not unanimous.

Price action is consolidating below resistance

LLY stock is trading at $1,429.31, down 1.94% over the last 24 hours, after a session range of $1,424.55 to $1,476.99. The stock is sitting just above its 20-day simple moving average at $1,411.52 and above its 50-day average at $1,295.59, which keeps the intermediate trend constructive. The 7-day SMA at $1,437.05 is close to spot, so the name is essentially pausing around the short-term trend line rather than breaking down.

The bigger point is resistance. Immediate resistance is marked at $1,462.68, with stronger resistance at $1,496.06 and the upper Bollinger Band at $1,471.07. That lines up with a stock that has strong underlying momentum but is no longer in a clean breakout phase. Daily RSI at 63.93 is still neutral-to-firm, while the MACD histogram sits at 0.0000, which does not support an aggressive momentum chase right here.

Derivatives positioning looks cautious, not euphoric

Binance perpetual futures show a neutral 8-hour funding rate of 0.0000%, which argues against crowded leverage on either side. Open interest is 2,312.03 contracts, down 1.13% over 24 hours, suggesting some position trimming rather than fresh buildup.

The long/short splits lean bearish across Binance cohorts: global accounts are 43.2% long versus 56.8% short, and top traders are 41.2% long versus 58.8% short. That should be read carefully: these ratios describe Binance futures positioning, not the shareholder base or equity fundamentals. Against that, the taker buy/sell ratio of 1.4888 shows aggressive buying pressure in the near term. The result is a mixed tape: directional hesitation in positioning, but active dip-buying in flow.

What would change the setup

For bulls, the near-term test is whether LLY can reclaim and hold above $1,462.68, then challenge $1,471.07 and $1,496.06. A move through that zone would confirm that the post-earnings pullback is only a pause inside the broader uptrend.

For bears, the line in the sand is $1,410.24. A clean break below that level would put the 20-day moving average and the lower Bollinger structure back in play, with $1,391.18 as the next major support. In that case, the market would be signaling that the stock needs more time to digest the sharp run rather than immediately extending it.

There is no date-specified next catalyst in the evidence provided, so the near-term focus is simply whether Lilly can hold the post-earnings advance and defend the moving-average shelf.

Sign in to save this article Free account: build your research collection and return to read it anytime.